{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:07:59Z","timestamp":1792591679458,"version":"4.5.0"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dupilumab is approved for moderate\u2010severe atopic dermatitis (AD) in patients aged \u22656\u2009months by the US Food and Drug Administration and Health Canada; however, there are little real\u2010world data because providers have limited practical experience with this recently approved therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe the real\u2010world effectiveness and safety in patients aged &lt;12\u2009years with moderate\u2010severe AD currently receiving or previously having received dupilumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter retrospective study was conducted at six Canadian sites. Cases were divided into Group 1 \u22642\u2009years old, Group 2 &gt;2 to &lt;6\u2009years old, and Group 3 \u22656 to &lt;12\u2009years old. Medical history and details of dupilumab treatment were collected. The primary outcome was to measure the improvement in eczema area and severity index. Secondary outcomes examined included the children's dermatology life quality index\/infant's dermatitis quality of life, peak pruritus numerical rating scale, and delay to dupilumab access for patients who were considered off\u2010label for dupilumab due to their age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty three pediatric patients (37 males) with moderate\u2010to\u2010severe AD were included; the mean age was 6.4\u2009years old (range: 2\u201311) when dupilumab treatment was started. Overall, 75% (36\/48) achieved EASI\u201075% and 71% (34\/48) achieved EASI\u201090. EASI\u201075 and EASI\u201090 were achieved in 90% (17\/19) and 73% (12\/19) in patients &lt;6\u2009years old, and 76% (22\/29) and 59% (17\/29) in patients &gt;6\u2009years old, respectively. No serious adverse events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dupilumab is safe and effective for patients under the age of 12. However, even for experienced providers, access to the medication was challenging.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pde.15418","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T14:59:20Z","timestamp":1698764360000},"page":"5-11","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multicenter Canadian case series of pediatric patients less than 12\u2009years of age with moderate\u2010to\u2010severe atopic dermatitis treated with dupilumab"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-5229","authenticated-orcid":false,"given":"Sylvia","family":"Martinez\u2010Cabriales","sequence":"first","affiliation":[{"name":"Alberta Children's Hospital, Department of Pediatrics University of Calgary  Calgary Canada"},{"name":"Division of Dermatology, Department of Medicine University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Marcoux","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Pediatrics, Sainte\u2010Justine University Hospital Center University of Montreal  Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Liy\u2010Wong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Dermatology and Rheumatology, Children's Hospital of Eastern Ontario University of Ottawa  Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Dermatology Research Institute  Calgary Canada"},{"name":"Division of Dermatology, Department of Medicine University of Calgary  Calgary Canada"},{"name":"Section of Community Pediatrics, Department of Pediatrics University of Calgary  Calgary Canada"},{"name":"Section of Pediatric Rheumatology, Department of Pediatrics University of Calgary  Calgary Canada"},{"name":"Skin Health &amp; Wellness Centre  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine University of Toronto  Toronto Canada"},{"name":"The Hospital for Sick Children and Department of Pediatrics University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, IWK Health Centre Dalhousie University  Halifax Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla","family":"Lansang","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine University of Toronto  Toronto Canada"},{"name":"The Hospital for Sick Children and Department of Pediatrics University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Tonkin","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Joseph","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine University of Toronto  Toronto Canada"},{"name":"The Hospital for Sick Children and Department of Pediatrics University of Toronto  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wong","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Alberta  Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna","family":"Spring","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Dermatology and Rheumatology, Children's Hospital of Eastern Ontario University of Ottawa  Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gavigan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Dermatology and Rheumatology, Children's Hospital of Eastern Ontario University of Ottawa  Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-3611","authenticated-orcid":false,"given":"Michele","family":"Ramien","sequence":"additional","affiliation":[{"name":"Alberta Children's Hospital, Department of Pediatrics University of Calgary  Calgary Canada"},{"name":"Division of Dermatology, Department of Medicine University of Calgary  Calgary Canada"},{"name":"Section of Community Pediatrics, Department of Pediatrics University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.054"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16928"},{"key":"e_1_2_8_4_1","unstructured":"FDA approves Dupixent\u00ae (dupilumab) as First biologic medicine for children aged 6 months to 5\u2009years with moderate\u2010to\u2010severe atopic dermatitis. Accessed May 16 2023https:\/\/www.prnewswire.com\/news-releases\/fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-301563406.html"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(22)01539\u20102"},{"key":"e_1_2_8_6_1","unstructured":"DUPIXENT\u00ae (dupilumab injection) now approved in Canada for children as young as six months old with severe atopic dermatitis. Accessed May 16 2023https:\/\/www.newswire.ca\/news-releases\/dupixent-r-dupilumab-injection-now-approved-in-canada-for-children-as-young-as-six-months-old-with-severe-atopic-dermatitis-846622202.html"},{"key":"e_1_2_8_7_1","unstructured":"Study to assess the long\u2010term safety of dupilumab administered in participants \u22656 months to <18\u2009years of age with atopic dermatitis (AD). Accessed May 16 2023https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02612454?view=results"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13697"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14933"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272\u2010022\u201000531\u20100"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.08.716"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13887"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.010"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.15418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T14:11:29Z","timestamp":1706537489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.15418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/pde.15418"],"URL":"https:\/\/doi.org\/10.1111\/pde.15418","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"2023-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}